Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity

被引：10

作者：

Lyne, Paul D. ^{[1
]}

Aquila, Brian ^{[1
]}

Cook, Donald J. ^{[1
]}

Dakin, Les A. ^{[1
]}

Ezhuthachan, Jay ^{[1
]}

Ioannidis, Stephanos ^{[1
]}

Pontz, Timothy ^{[1
]}

Su, Mei ^{[1
]}

Ye, Qing ^{[1
]}

Zheng, Xiaolan ^{[1
]}

Block, Michael H. ^{[1
]}

Cowen, Scott ^{[1
]}

Deegan, Tracy L. ^{[1
]}

Lee, John W. ^{[1
]}

Scott, David A. ^{[1
]}

Custeau, Dominique ^{[1
]}

Drew, Lisa ^{[1
]}

Poondru, Srinivasu ^{[1
]}

Shen, Minhui ^{[1
]}

Wu, Allan ^{[1
]}

机构：

[1] AstraZeneca R&D Boston, Canc Res, Waltham, MA 02451 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 03期

关键词：

B-Raf; V600E; Amidoheteroaryl; P38 MAP KINASE; ACTIVATION; MUTATIONS; CANCER; PATHWAY;

D O I：

10.1016/j.bmcl.2008.10.053

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of amidoheteroaryl compounds were designed and synthesized as inhibitors of B-Raf kinase. Several compounds from the series show excellent potency in biochemical, phenotypic and mode of action cellular assays. Potent examples from the series have also demonstrated good plasma exposure following an oral dose in rodents and activity against the Ras-Raf pathway in tumor bearing mice. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1026 / 1029

页数：4

共 50 条

[21] Activation mechanisms of clinically distinct B-Raf V600E and V600K mutants
Zhang, Mingzhen
Maloney, Ryan
Liu, Yonglan
Jang, Hyunbum
Nussinov, Ruth
CANCER COMMUNICATIONS, 2023, 43 (03) : 405 - 408
[22] A Look Inside of the Complex Pathogenesis of B-RAF(V600E)-Driven Cancer
Caputo, Emilia
THERANOSTICS, 2017, 7 (07): : 2108 - 2110
[23] Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer
Yao, Huixiang
Sun, Qun
Zhu, Jinshui
ARCHIV DER PHARMAZIE, 2016, 349 (10) : 808 - 815
[24] Suppression of B-Raf(V600E) cancers by MAPK hyper-activation
Atiq, Rawan
Hertz, Rachel
Eldad, Sophia
Smeir, Elia
Bar-Tana, Jacob
ONCOTARGET, 2016, 7 (14) : 18694 - 18704
[25] Mutant B-Raf Kinase Inhibitors as Anticancer Agents
Asati, Vivek
Bharti, Sanjay K.
Mahapatra, Debarshi K.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2016, 16 (12) : 1558 - 1575
[26] The identification of potent and selective imidazole-based inhibitors of B-Raf kinase
Takle, AK
Brown, MJB
Davies, S
Dean, DK
Francis, G
Gaiba, A
Hird, AW
King, FD
Lovell, PJ
Naylor, A
Reith, AD
Steadman, JG
Wilson, DM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (02) : 378 - 381
[27] Anti-DLL4 reduces tumor growth and tumorigenicity in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors
Beviglia, Lucia
Yeung, Pete
Fischer, Marcus
Yen, Wang-Ching
Gurney, Austin
Lewicki, John
Kapoun, Ann
Hoey, Timothy
CANCER RESEARCH, 2012, 72
[28] Noninvasive Drug Delivery Using Ultrasound: Targeting Melanoma Using siRNA Against Mutant (V600E) B-Raf
Tran, Melissa A.
Gowda, Raghavendra
Park, Eun-Joo
Adair, James
Smith, Nadine
Kester, Mark
Robertson, Gavin P.
8TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND, 2009, 1113 : 423 - +
[29] Discovery of highly potent and selective B-Raf Kinase inhibitors
Wang, Xiaolun
Berger, Dan M.
Salaski, Edward J.
Torres, Nancy
Hu, Yongbo
Jeremy, Levin I.
Powell, Dennis
Wojciechowicz, Donald
Collins, Karen
Frommer, Eileen
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[30] Discovery and optimization of potent and selective B-RAF kinase inhibitors
Wu, Hui
Lapierre, Jean-Marc
Namdev, Nivedita
Hutchins, Patrick
Moussa, Magdi
Tandon, Manish
Hill, Jason
Liu, Yanbin
Link, Jeff
Kizer, Darin
Bruseo, Charles
Szwaya, Jeff
Chen, Chang-Rung
France, Dennis
Ashwell, Mark A.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240

← 1 2 3 4 5 →